Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti BCMA chimeric antigen receptor T cell therapy - Chongqing Precision Biotech

Next Previous
Drug Profile

Anti BCMA chimeric antigen receptor T cell therapy - Chongqing Precision Biotech

Alternative Names: BCMA CAR-T cells - Chongqing Precision Biotech Co Ltd; Invivo CAR-T - Chongqing Precision Biotech; Invivo-PICX-CAR-T-Chongqing Precision Biotech

Latest Information Update: 29 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Precision Biotech Co., Ltd
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 20 Jul 2026 Chongqing Precision Biotech initiates a phase I trial for Multiple myeloma (Second-line therapy or greater) in China (IV, Infusion) (NCT07715630)
  • 01 Jan 2021 Chongqing Precision Biotech initiates a phase I/II trial in Multiple myeloma (In adults, In the elderly, Second-line therapy or greater) in China (IV, Infusion) (NCT04776330)
  • 01 Dec 2019 Chongqing Precision Biotech initiates a phase I/II trial in Multiple myeloma (Second-line therapy or greater) in China (IV, Infusion) (NCT04272151)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top